Month: August 2024

EPS of $(0.05), Adjusted EPS of $0.06, reflecting additional restructuring activity Adjusted EBITDA of $10.0 million, free cash flow of $6.4 million Strategic actions taken to strengthen Vehicle Solutions Business Provides updated guidance for full year 2024 NEW ALBANY, Ohio, Aug. 05, 2024 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI), a diversified industrial products and services company, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Highlights (Compared with prior year, where comparisons are noted)Revenues of $229.9 million, down 12.3%, due primarily to a global softening in customer demand. Operating income of $0.8 million, down 95.2%; adjusted operating income of $5.7 million, down 65.9%. The decrease in operating income was driven primarily by lower sales volumes, partially offset...

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE: VNO) reported today: Quarter Ended June 30, 2024 Financial Results NET INCOME attributable to common shareholders for the quarter ended June 30, 2024 was $35,260,000, or $0.18 per diluted share, compared to $46,377,000, or $0.24 per diluted share, for the prior year’s quarter. FUNDS FROM OPERATIONS (“FFO”) attributable to common shareholders plus assumed conversions (non-GAAP) for the quarter ended June 30, 2024 was $148,944,000, or $0.76 per diluted share, compared to $144,059,000, or $0.74 per diluted share, for the prior year’s quarter. Adjusting for the items that impact period-to-period comparability listed in the table on the following page, FFO attributable to common shareholders plus assumed conversions, as adjusted (non-GAAP)...

Gross Margin of 33.6% Leads to Net Earnings of $36.3 Million, and EPS of $1.87 and Adjusted EPS of $1.98 MOUNT LAUREL, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) — J&J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial results for the third quarter ended June 29, 2024.    Third QuarterActuals $ vs. LY % vs. LYNet Sales $440.0M $14.2M 3.3%Operating Income $50.1M $1.8M 3.8%Net Earnings $36.3M $1.3M 3.8%Earnings per Diluted Share $1.87 $0.06 3.3%       Adjusted Operating Income $53.1M $2.0M 3.9%Adjusted EBITDA $70.9M $4.2M 6.3%Adjusted Earnings per Diluted Share $1.98 $0.06 3.1%This press release contains non-GAAP financial measures. Please refer to the Non-GAAP Financial Measures section below for reconciliations to the most comparable GAAP measures. Dan Fachner, J&J Snack...

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist Top-line data accelerated and now anticipated in Q1 2025 for Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Top-line data now anticipated in Q1 2026 for Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab IND accepted by FDA for ANB033, our anti-CD122 antagonist; Phase 1 trial initiation anticipated in Q4 2024SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. “We’ve had an exceptional quarter as we...

Increased Net Sales 9.2 percent to $356.7 Million Reported Net Income per Diluted Share of $0.30 Achieved Record Adjusted Net Income per Diluted Share of $0.32 Raises Annual Guidance for Net Sales and Adjusted EBITDA ATLANTA, Aug. 05, 2024 (GLOBE NEWSWIRE) — Mueller Water Products, Inc. (NYSE: MWA) announced financial results for its 2024 third quarter ended June 30, 2024. In the third quarter of 2024, the Company:Delivered net sales of $356.7 million, a 9.2 percent increase as compared with $326.6 million in the prior year quarter Reported operating income of $67.0 million as compared with $35.6 million in the prior year quarter and increased adjusted operating income 77.0 percent to $69.9 million as compared with $39.5 million in the prior year quarter Reported operating margin of 18.8 percent as compared with 10.9 percent...

Record Second Quarter 2024 Revenue Increased 33% Year-over-Year WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business HighlightsHelped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023 Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarter Grew worldwide Trauma & Deformity revenue 37%, worldwide Scoliosis revenue 26%; Sports Medicine/Other revenue...

LA JOLLA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $25.7 million, or $1.00 per diluted share, for the second quarter of 2024 compared to net income of $17.6 million, or $0.69 per diluted share, for the second quarter of 2023. Adjusted net income(1) was $32.0 million, or $1.25 per diluted share, for the second quarter of 2024 as compared to $21.8 million, or $0.86 per diluted share, for the second quarter of 2023. Second Quarter 2024 HighlightsGross written premiums increased by 40.4% to $385.2 million compared to $274.3 million in the second quarter of 2023 Net income of $25.7 million, compared to $17.6 million in the second quarter of 2023 Adjusted net income(1) of $32.0 million, compared to $21.8 million in the second quarter of 2023 Total...

FORT MYERS, Fla. , Aug. 05, 2024 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico”, the “Company”, “we”, “us” or “our”) (Nasdaq: ALCO) today announced financial results for the third quarter of fiscal year 2024 and the nine months ended June 30, 2024, the highlights of which are as follows:The Company previously announced that it entered a new three-year agreement to sell oranges to Tropicana at prices that are approximately 33% to 50% higher, over the life of the contract, than the average price for all the citrus fruit sold to Tropicana last season. The Company has now treated substantially all of its producing trees with Oxytetracycline (“OTC”) and anticipates that these 4.5 million trees will support meaningful production growth in the 2024-25 harvest season. The Company previously announced that it has continued to commit to its real...